Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases

Annals of Surgical Oncology

Volumn 10, Issue 2, 2003, Pages 136-143

  Safford, Shawn D ^a   Goyeau, Dominique ^a   Freemerman, Alex J ^a   Bentley, Rex ^a   Everett, Mary Lou ^a   Grundy, Paul E ^b   Skinner, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Chromosome 16; Loss of heterozygosity; Neoplasia; Tumor suppressor; Wilms' tumor

Indexed keywords

CADHERIN; TRANSCRIPTION FACTOR E2F4; UVOMORULIN; MICROSATELLITE DNA;

ARTICLE; CHROMOSOME 16Q; CHROMOSOME MAP; CHROMOSOME NOR; CONSENSUS DEVELOPMENT; CONSENSUS SEQUENCE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEPHROBLASTOMA; POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR SUPPRESSOR GENE; CHROMOSOME 16; ENZYME IMMUNOASSAY; GENETIC MARKER; GENETICS; KIDNEY TUMOR; NONPARAMETRIC TEST;

CADHERINS; CHROMOSOMES, HUMAN, PAIR 16; GENES, TUMOR SUPPRESSOR; GENES, WILMS TUMOR; GENETIC MARKERS; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; WILMS TUMOR;

EID: 0038283092     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.03.038     Document Type: Article

References (22)

1. Slater R, Mannens M. Cytogenetics and molecular genetics of Wilms' tumor of childhood. Cancer Genet Cytogenet 1992;61:111-21.
2. Mason JE, Goodfellow PG, Grundy PE, Skinner MA. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor. J Pediatr Surg 2000;35:891-7.
3. Wadey RB, Pal N, Buckle B, Yeomans E, Pritchard J, Cowell JK. Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11. Oncogene 1990;5:901-7.
4. Koufos A, Grundy PE, Morgan K, et al. Familial Weidemann-Beckwith syndrome and a second Wilms' tumor locus both map to 11p15.5. Am J Hum Genet 1989;44:711-9.
5. Fearon E, Vogelstein B, Feinberg AP. Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumors. Nature 1984;309:176-8.
6. Maw MA, Grundy PE, Millow LJ, et al. A third Wilms' tumor locus on chromosome 16q. Cancer Res 1992;52:3094-8.
7. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosome 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994;54:2331-3.
8. Grundy PE, Telzerow PE, Moksness J, Breslow NE. Clinicopathologic correlates of loss of heterozygosity for chromosome 16q and 1p in Wilms' tumor: a preliminary analysis. Med Pediatr Oncol 1996;27:429-33.
9. Grundy RG, Pritchard J, Scrambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumor. Br J Cancer 1998;78:1181-7.
10. Becker K, Atkinson M, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-53.
11. Soler AP, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999;86:1263-72.
12. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-9.
13. Graff JR, Gabrielson E, Fuji H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000;275:2727-32.
14. Bringuier P, Umbas R, Schaafsma H, Karthaus H, Debruyne F, Schalken J. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993;53:3241-5.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
16. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997;272:22322-22329.
17. Klamt B, Schulze M, Thate C, et al. Allele loss in Wilms tumors of chromosome amis 11q, 16q, and 22q correlates with clinicopathological parameters. Genes Chromosomes Cancer 1998;22:287-94.
18. Schulz S, Becker K-F, Braungart E, et al. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours. J Pathol 2000;191:162-9.
19. Liotta L, Steeg P, Stetler-Stevenson W. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
20. Behrens J, Mareel M, Van Roy F, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989;108:2435-47.
21. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-2.
22. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001;7:594-9.